SEPN Septerna, Inc.

P/E --

Forward P/E -21.319128

Price/Sales 19.533304

Beta 2.282

Div Yield 0.0%

Market Cap --

Company Analysis

Latest News

November 04, 2026

Septerna Selects SEP-204 for Graves' Disease, Plans Phase 1 Trial for Q1 2027

Septerna, Inc. announced the selection of SEP-204 as its development candidate for treating Graves' disease and thyroid eye disease (TED). The company reported...